Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this large comparative effectiveness study led by Richard J. Barohn, MD, of the University of Kansas Medical Center, is to learn about the safety and effectiveness of nortriptyline, duloxetine, pregabalin and mexiletine in treating cryptogenic sensory polyneuropathy (CSPN).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Kansas Medical Center
• Collaborator: Patient-Centered Outcomes Research Institute
• Treatments: Duloxetine Hydrochloride; Mexiletine; Nortriptyline; Pregabalin

Criteria

Inclusion Criteria:

• Diagnosis of cryptogenic sensory polyneuropathy.

• Likert Pain Score of greater than or equal to 4.

• Must not currently be on nortriptyline, duloxetine, pregabalin or mexiletine or similar class of medication for at least 7 days from baseline study visit.

Exclusion Criteria:

• Any medical condition or current medication that would prevent them from taking either nortriptyline, duloxetine, pregabalin or mexiletine.

• Unable to give consent.

• Unable or not willing to comply with the study.

• Other causes for polyneuropathy.